Premium
Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin
Author(s) -
POPERT R. J. M.,
GOODALL J.,
COPTCOAT M. J.,
THOMPSON P. M.,
PARMAR M. K. B.,
MASTERS J. R. W.
Publication year - 1994
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1994.tb16585.x
Subject(s) - epirubicin , bladder cancer , medicine , urology , urinary bladder , cancer , urinary bladder cancer , oncology , breast cancer
Objective To determine the response of a marker tumour to a single instillation of intravesical epirubicin. Patients and methods Eighty‐one patients (54 men, 27 women) with a mean age of 69.3 years (range 36–92) with superficial bladder cancer were randomized to receive a single instillation of intravesical epirubicin. At the initial cystoscopy all but one papillary marker tumour was resected. Subsequently the patients were a randomized to receive either intravesical epirubicin at a concentration of 1 mg/ml (n=40) or 2 mg/ml ( n =41) in 50 ml of saline for 1h. THe response of the marker tumour was determined at 3 months (first check cystoscopy). The toxicity associated with both treatments was also recorded. Results A complete response (no visible or microscopic bladder carcinoma) was observed in 46% (95% confidence interval (CI) 35–57%) of a patients. No patient experienced systemic side‐effects. Chemical cystitis and bladder irritability were the most frequent local sideeffects, occurring in 15% (95% CI 8 ‐ 24%) of the patients. Conclusions A single instillation of intravesical epirubicin has a demonstrable effect in superficial bladder cancer. The results compare farvourably with more onerous regimes. Side‐effects were minimal at 1 mg/ml and acceptable at 2 mg/ml.